Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process

Area of Science:

• Pharmacology and Drug Development
• Regulatory Science
• Patient Safety

Background:

• The Zecuity® sumatriptan iontophoretic transdermal system, used for acute migraine treatment, was withdrawn due to widespread reports of burns and scarring.
• FDA data revealed 2889 safety reports, with 904 classified as serious, highlighting significant patient harm associated with the patch.

Purpose of the Study:

• To analyze publicly available data on patient harm linked to the iontophoretic sumatriptan patch.
• To identify failures in the drug's development, approval, and marketing process.
• To propose strategies for preventing similar issues in future drug development.

Main Methods:

• A narrative review of US Food and Drug Administration (FDA) documents, clinical trial registries, and public domain information (PubMed, Google, social media).
• Examination of the new drug application, approval process, marketing, and reported complications of the Zecuity patch.

Main Results:

• The FDA was aware of burn and scarring risks before approval, initially rejecting the application due to safety and quality concerns.
• Despite reviewer concerns, the reapplication was approved with enhanced postmarketing requirements, yet product labeling omitted burn risks.
• Suboptimal adverse event reporting in clinical trials and aggressive marketing may have skewed safety perceptions, while social media documented patient harm.

Conclusions:

• Significant issues were identified in the development, testing, approval, and marketing phases of the Zecuity patch.
• Examining this high-profile failure offers critical lessons for improving the drug development and regulatory oversight process for headache treatments.